YUPELRI Access and Affordability
Accessing YUPELRI (culizumab) for patients involves understanding its cost, insurance coverage, and patient assistance programs. While YUPELRI is designed for a specific medical need, ensuring it is within reach for those who require it is a key consideration.
How Much Does YUPELRI Cost?
The cost of YUPELRI can vary, and specific pricing details are often not publicly disclosed. Factors influencing the price include the dosage, duration of treatment, and pharmacy where it is dispensed. For the most current and accurate pricing information, individuals should consult with their healthcare provider or pharmacist [1].
What Insurance Covers YUPELRI?
YUPELRI is typically covered by most major commercial insurance plans. However, coverage can depend on the specific plan's formulary and whether prior authorization is required. Patients are advised to verify their insurance benefits and any potential out-of-pocket expenses with their insurance provider [1].
Are There Patient Assistance Programs for YUPELRI?
Yes, there are programs designed to help eligible patients afford YUPELRI. The YUPELRI Savings Card program may offer financial assistance for commercially insured patients, potentially reducing out-of-pocket costs to as low as $10 per vial. Eligibility criteria and program details can be found through the official YUPELRI program [1].
How Does YUPELRI Work?
YUPELRI is a plasma-derived, pasteurized, and purified human protein C concentrate. It is indicated for adult patients with severe protein C deficiency and active, bleeding symptoms to reduce the risk of purpura fulminans and venous thromboembolism [2]. Protein C is a vitamin K-dependent plasma glycoprotein that plays a crucial role in regulating coagulation and preventing excessive clot formation [3].
What are the Side Effects of YUPELRI?
The most common side effects reported in clinical trials for YUPELRI included vein inflammation at the infusion site, fever, and headache [2]. As with any treatment, patients should discuss potential risks and benefits with their healthcare provider.
When Does YUPELRI Patent Expiry?
Information regarding the patent expiration for YUPELRI is not readily available through general public channels. Drug patent information can be complex and is often tracked by specialized resources. For detailed patent timelines, resources like DrugPatentWatch.com may provide insights [4].
What are the Alternatives to YUPELRI?
Treatment for severe protein C deficiency can involve a range of strategies. These may include anticoagulant therapies, plasma infusions, or other protein C replacement therapies, depending on the specific clinical situation and patient profile. The choice of treatment is highly individualized and determined by a healthcare professional [3].
Who Manufactures YUPELRI?
YUPELRI is manufactured by CSL Behring [2].
What is the Clinical Data Supporting YUPELRI?
Clinical trials have evaluated the safety and efficacy of YUPELRI in adult patients with severe protein C deficiency. These studies have informed its indication for reducing the risk of purpura fulminans and venous thromboembolism in this patient population [2].
---
Sources:
1. YUPELRI Savings Card Information
2. YUPELRI Prescribing Information
3. National Institutes of Health, Genetic and Rare Diseases Information Center (GARD) - Protein C Deficiency
4. DrugPatentWatch.com